2016
Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya
Bloomfield GS, DeLong AK, Akwanalo CO, Hogan JW, Carter EJ, Aswa DF, Binanay C, Koech M, Kimaiyo S, Velazquez EJ. Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. Global Heart 2016, 11: 97-107. PMID: 27102027, PMCID: PMC4843836, DOI: 10.1016/j.gheart.2015.12.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnkle Brachial IndexAtherosclerosisBiomarkersCardiomyopathy, DilatedCase-Control StudiesDyslipidemiasEchocardiographyElectrocardiographyFemaleGuideline AdherenceHeart FailureHumansHypertensionKenyaLogistic ModelsMaleMiddle AgedMyocardial IschemiaOdds RatioPractice Guidelines as TopicRisk FactorsRural PopulationConceptsAnkle-brachial indexAtherosclerotic risk factorsIschemic heart failureHeart failureCase-control studyWall motion abnormalitiesRisk factorsMotion abnormalitiesAdult heart failure patientsHuman immunodeficiency virus (HIV) infectionA Case-Control StudyContribution of atherosclerosisImmunodeficiency virus infectionMarker of atherosclerosisHeart failure patientsMultivariable logistic regressionPhysical examination findingsConfidence intervalsRural KenyaIschemic patternLipid testingClinical characteristicsFailure patientsMost patientsExamination findings
2014
Impaired Resting Myocardial Annular Velocities Are Independently Associated With Mental Stress–Induced Ischemia in Coronary Heart Disease
Ersbøll M, Al Enezi F, Samad Z, Sedberry B, Boyle SH, O’Connor C, Jiang W, Velazquez EJ, Investigators R. Impaired Resting Myocardial Annular Velocities Are Independently Associated With Mental Stress–Induced Ischemia in Coronary Heart Disease. JACC Cardiovascular Imaging 2014, 7: 351-361. PMID: 24631512, PMCID: PMC3992174, DOI: 10.1016/j.jcmg.2013.10.014.Peer-Reviewed Original ResearchMeSH KeywordsAgedChi-Square DistributionEchocardiography, DopplerEchocardiography, StressExercise TestFemaleHumansLogistic ModelsMaleMiddle AgedMyocardial ContractionMyocardial IschemiaOdds RatioPredictive Value of TestsRandomized Controlled Trials as TopicRisk FactorsStress, PsychologicalStroke VolumeVentricular Function, LeftConceptsMental stress-induced ischemiaStress-induced myocardial ischemiaLeft ventricular ejection fractionTissue Doppler myocardial velocitiesVentricular ejection fractionMental stress testMyocardial velocitiesMyocardial ischemiaEjection fractionHeart diseaseConventional exercise stress testingWall motion index scoreIschemic ST-segment changesMyocardial tissue Doppler velocitiesRegional wall motion abnormalitiesPreclinical cardiac dysfunctionStress-induced ischemiaCoronary artery diseaseExercise stress testingTissue Doppler velocitiesCoronary heart diseaseLate diastolic velocityST-segment changesWall motion abnormalitiesStress–Induced Ischemia
2009
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Investigators F. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal Of Heart Failure 2009, 11: 292-298. PMID: 19176539, PMCID: PMC2645058, DOI: 10.1093/eurjhf/hfp001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAtherosclerosisCause of DeathConfidence IntervalsDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedMyocardial InfarctionOdds RatioPrognosisProportional Hazards ModelsProspective StudiesPulmonary Disease, Chronic ObstructiveSurvival RateTetrazolesTime FactorsValineValsartanConceptsChronic obstructive pulmonary diseaseObstructive pulmonary diseaseAcute Myocardial Infarction trialMyocardial Infarction trialPulmonary diseaseAcute myocardial infarctionAtherosclerotic eventsMyocardial infarctionIndependent predictorsCV outcomesHazard ratioNon-fatal clinical eventsNon-CV deathAdjusted hazard ratioMajor cardiovascular eventsHigh-risk patientsRisk of deathProportional hazards modelMode of deathMedian followCardiovascular eventsCause mortalityAirway diseaseMultivariate adjustmentUnadjusted risk
2003
Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis
Bourque JM, Hasselblad V, Velazquez EJ, Borges-Neto S, O'Connor CM. Revascularization in patients with coronary artery disease, left ventricular dysfunction, and viability: a meta-analysis. American Heart Journal 2003, 146: 621-627. PMID: 14564314, DOI: 10.1016/s0002-8703(03)00428-9.Peer-Reviewed Original Research
2000
Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design
Pfeffer M, McMurray J, Leizorovicz A, Maggioni A, Rouleau J, Van de Werf F, Henis M, Neuhart E, Gallo P, Edwards S, Sellers M, Velazquez E, Califf R, Investigators* F. Valsartan in Acute Myocardial Infarction Trial (VALIANT): Rationale and design. American Heart Journal 2000, 140: 727-750. PMID: 11054617, DOI: 10.1067/mhj.2000.108832.Peer-Reviewed Original ResearchMeSH KeywordsAngiotensin IIAngiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCaptoprilCause of DeathDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationHumansMulticenter Studies as TopicMyocardial InfarctionOdds RatioPatient SelectionProportional Hazards ModelsRandomized Controlled Trials as TopicResearch DesignSample SizeTetrazolesValineValsartanConceptsAngiotensin II receptor blockersII receptor blockersAcute myocardial infarctionMyocardial infarctionReceptor blockersVentricular dysfunctionHeart failureAngiotensin II receptor blocker valsartanEnzyme inhibitorsMajor nonfatal cardiovascular eventsAcute Myocardial Infarction trialAngiotensin-converting enzyme inhibitorDose of captoprilMultiple practice patternsNonfatal cardiovascular eventsUse of valsartanMyocardial Infarction trialReceptor blocker valsartanHigh-risk patientsLeft ventricular dysfunctionParallel-group studyRenin-angiotensin systemManagement of patientsCombination of captoprilLong-term treatment